atazanavir sulfate has been researched along with Bilirubinemia in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (33.33) | 29.6817 |
| 2010's | 28 (62.22) | 24.3611 |
| 2020's | 2 (4.44) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, WW; Li, M; Zucker, SD | 1 |
| Agide, FD; Mohraz, M; Nikfar, S; Tigabu, BM | 1 |
| Culley, CL; Ensom, MH; Gilchrist, SE; Kiang, TK | 1 |
| Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Karolia, Z; Moyle, G; Ringner-Nackter, L; Seymour, N; Yapa, MH | 1 |
| Chang, JH; Cheong, J; Ho, Q; Lin, M; Plise, E | 1 |
| Bertz, R; Botes, M; Conradie, F; Eley, T; Hardy, H; Huang, SP; Josipovic, D; McGrath, D; Osiyemi, O; Zorrilla, CD | 1 |
| Baril, JG; Dufresne, S; Laprise, C; Trottier, H | 1 |
| Bow, DA; Chiou, WJ; de Morais, SM; Kikuchi, R; Li, X; Voorman, RL | 1 |
| Atrio, JM; Chen, KT; Posada, R; Rodriguez Caprio, G; Sperling, RS | 1 |
| Bernardino, JI; Carton, JA; Curran, A; Domingo, P; Ferrer, E; Gatell, JM; Gonzalez-Cordon, A; Gutierrez, F; Martinez, E; Murillas, J; Negredo, E; Peraire, J; Perez, I; Pich, J; Podzamczer, D; Portilla, J; Santos, I | 1 |
| Antoniadou, A; Detsika, M; Hatzakis, A; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Paraskevis, D; Petrikkos, G; Protopapas, K; Sypsa, V | 1 |
| Daar, ES; Haas, DW; Johnson, DH; McLaren, PJ; Morse, GD; Ritchie, MD; Venuto, C | 1 |
| Bourgeois-Moine, A; Bourse, P; Calvez, V; Damond, F; Descamps, D; Dommergues, M; Duro, D; Faucher, P; Ichou, H; Landman, R; Lariven, S; Lê, MP; Legac, S; Mandelbrot, L; Matheron, S; Meier, F; Mortier, E; Peytavin, G; Soulié, C; Tubiana, R; Valantin, MA | 1 |
| Avihingsanon, A; Gorowara, M; Kerr, SJ; Punyawudho, B; Ruxrungtham, K; Shotelersuk, V; Suphapeetiporn, K; Tongkobpetch, S | 1 |
| Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Ferraris, L; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Minisci, D; Molinari, L; Riva, A; Rizzardini, G | 1 |
| Alvarellos, M; Brummel, SS; Caudle, KE; Court, MH; Gammal, RS; Gaur, AH; Guillemette, C; Haas, DW; Haidar, CE; Iwuchukwu, OF; Klein, TE; Lennox, JL; Ratain, MJ; Schackman, BR; Whirl-Carrillo, M | 1 |
| Chang, SC; Chang, SY; Hung, CC; Kuo, CH; Lin, SW; Liu, WC; Su, YC; Sun, HY; Tang, SY; Tsai, MS; Wu, BR | 1 |
| Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A | 1 |
| Listowsky, I; Roy-Chowdhury, J; Roy-Chowdhury, N; Wolkoff, AW | 1 |
| Roca, B | 1 |
| Barreiro, P; González, M; Gonzalez-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Antinori, A; Antonucci, F; Carosi, G; Castelnuovo, F; De Luca, A; Di Perri, G; Esposito, R; Lapadula, G; Lazzarin, A; Maggiolo, F; Maserati, R; Migliorino, G; Paraninfo, G; Quirino, T; Rizzardini, G; Torti, C | 1 |
| Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Navarra, P; Prosperi, M; Ragazzoni, E | 1 |
| López-Cortés, LF | 1 |
| Gatell, JM; Zamora, L | 1 |
| González, M; Palacios, R; Ruiz, J; Santos, J | 1 |
| Camacho, A; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| Choe, KW; Choe, PG; Jeon, JH; Kim, HB; Kim, NJ; Oh, MD; Park, SW; Park, WB; Song, KH | 1 |
| Choe, PG; Kim, HB; Kim, NH; Kim, NJ; Oh, MD; Park, SW; Park, WB; Song, JS; Song, KH | 1 |
| Bellón, JM; González, MI; José, MI; Larru, B; Mellado, MJ; Muñoz-Fernández, MÁ; Navarro, ML; Nso Roca, AP; Nso, AP; Ramos, JT | 1 |
| Agnes, G; Basso, RP; de Almeida, S; Kuhmmer, R; Lazzaretti, RK; Mattevi, VS; Pinheiro, CA; Ribeiro, JP; Silveira, JM; Silveira, MF; Sprinz, E; Turatti, L | 1 |
| Blanton, LS; East, J | 1 |
| Aubry, C; Badens, C; Javelle, E; Oliver, M; Savini, H; Simon, F | 1 |
| Butcher, D; Farajallah, A; Hu, W; Juethner, S; McDonald, C; McGrath, D; Moyle, G; Uy, J; Wirtz, V | 1 |
| Baker, P; Bradbeer, C; George, M; Ngwenya, S | 1 |
| Bissio, E; Espinola, L; Gadano, A; Gallego, P; Lopardo, G; Stambullian, M | 1 |
| Bissio, E; Lopardo, GD | 1 |
| Laurence, J | 1 |
| Sulkowski, MS | 1 |
| Barreiro, P; Barrios, A; Corral, A; González-Lahoz, J; Jiménez-Nacher, I; Rendón, A; Rodríguez Nóvoa, S; Soriano, V | 1 |
| Behrens, G; Lankisch, TO; Manns, MP; Moebius, U; Schmidt, RE; Strassburg, CP; Wehmeier, M | 1 |
| Barreiro, P; González-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Martín-Carbonero, L; Rodríguez-Nóvoa, S; Soriano, V | 1 |
| De Marez, T; De Paepe, E; De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Spinosa-Guzman, S; Vangeneugden, T | 1 |
| Battegay, M; Bodmer, M; Elzi, L; Haschke, M; Krähenbühl, S; Kummer, O; Mossdorf, E | 1 |
10 review(s) available for atazanavir sulfate and Bilirubinemia
| Article | Year |
|---|---|
Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lopinavir; Ritonavir; Treatment Outcome; Viral Load | 2020 |
Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.
Topics: Alleles; Anti-HIV Agents; Atazanavir Sulfate; Glucuronosyltransferase; HIV Infections; Homozygote; Humans; Hyperbilirubinemia; Oligopeptides; Polymorphism, Genetic; Prospective Studies; Pyridines; Retrospective Studies | 2013 |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
Topics: Atazanavir Sulfate; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Jaundice; Liver; Pharmacogenetics; Phenotype; Risk Assessment; Risk Factors | 2016 |
Pharmacogenomics of antiretrovirals.
Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Drug Hypersensitivity; Drug Resistance, Viral; Dyslipidemias; Genetic Predisposition to Disease; Genetic Testing; Glucuronosyltransferase; HLA Antigens; Humans; Hyperbilirubinemia; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Patents as Topic; Patient Selection; Pharmacogenetics; Pyridines; Ritonavir | 2008 |
[Pharmacology, pharmacokinetic features and interactions of atazanavir].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; Biotransformation; Blood Proteins; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Fetal Blood; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Infant, Newborn; Kidney Diseases; Liver Diseases; Maternal-Fetal Exchange; Metabolic Clearance Rate; Molecular Structure; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pyridines | 2008 |
[Efficacy of atazanavir in simplification regimens].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Oligopeptides; Pyridines; Ritonavir; Salvage Therapy; Treatment Outcome | 2008 |
[Adverse effects of atazanavir].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbohydrate Metabolism; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Gastrointestinal Diseases; Glucose; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Hyperinsulinism; Insulin Resistance; Oligopeptides; Pyridines; Urolithiasis | 2008 |
[Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cohort Studies; Disease Progression; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Insulin Resistance; Liver; Liver Cirrhosis; Multicenter Studies as Topic; Oligopeptides; Pyridines | 2008 |
[Clinical utility of atazanavir].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Cohort Studies; Comorbidity; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Insulin Resistance; Oligopeptides; Patient Acceptance of Health Care; Pyridines; Ritonavir; Salvage Therapy; Treatment Outcome; Viral Load | 2008 |
HIV therapeutics, continued: another HIV protease inhibitor approved.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Approval; Drug Resistance, Viral; Headache; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Hypercholesterolemia; Nausea; Oligopeptides; Patient Selection; Pyridines; Treatment Outcome; United States; United States Food and Drug Administration; Viral Load | 2003 |
7 trial(s) available for atazanavir sulfate and Bilirubinemia
| Article | Year |
|---|---|
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Bilirubin; Confidence Intervals; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Young Adult; Zinc Sulfate | 2013 |
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Female; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Infant, Newborn; Oligopeptides; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyridines; Ritonavir | 2013 |
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Darunavir; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Spain; Sulfonamides | 2014 |
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Female; Genome-Wide Association Study; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polymorphism, Single Nucleotide; Prospective Studies; Pyridines; Ritonavir | 2014 |
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV-1; Humans; Hyperbilirubinemia; Lopinavir; Male; Medication Adherence; Oligopeptides; Pyridines; Quality of Life; Ritonavir; Surveys and Questionnaires | 2012 |
Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Fasting; Female; HIV Infections; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Serum | 2013 |
Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Atazanavir Sulfate; Chromatography, Liquid; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Female; Half-Life; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Nausea; Oligopeptides; Pyridines; Sulfonamides; Tandem Mass Spectrometry; Time Factors; Vomiting | 2007 |
28 other study(ies) available for atazanavir sulfate and Bilirubinemia
| Article | Year |
|---|---|
Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
Topics: Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Ischemic Stroke; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Time Factors | 2020 |
Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.
Topics: Atazanavir Sulfate; Bilirubin; Cell Line; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indinavir; Liver-Specific Organic Anion Transporter 1; Models, Biological; Oligopeptides; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyridines; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2013 |
Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Follow-Up Studies; HIV Infections; Humans; Hyperbilirubinemia; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Oligopeptides; Proportional Hazards Models; Prospective Studies; Pyridines; Treatment Outcome | 2013 |
In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
Topics: Antirheumatic Agents; Atazanavir Sulfate; Bilirubin; Carbamates; Cyclosporine; Furans; Glucuronosyltransferase; HIV Protease Inhibitors; Hyperbilirubinemia; In Vitro Techniques; Indinavir; Liver-Specific Organic Anion Transporter 1; Oligopeptides; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyridines; Rifampin; Rifamycins; Saquinavir; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides | 2014 |
Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Hyperbilirubinemia; Infant, Newborn; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Prevalence; Pyridines; Risk Assessment | 2013 |
High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Cross-Sectional Studies; Glucuronosyltransferase; Greece; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Middle Aged; Oligopeptides; Pharmacogenetics; Polymorphism, Genetic; Prevalence; Pyridines; Ritonavir | 2014 |
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Administration Schedule; Drug Combinations; Female; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Viral Load | 2015 |
Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Genetic Testing; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pharmacogenetics; Pyridines | 2015 |
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Nephrolithiasis; Ritonavir; Viral Load | 2015 |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic st
Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Drug Combinations; Drug Monitoring; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lamivudine; Male; Middle Aged; Peroxisome-Targeting Signal 1 Receptor; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2017 |
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.
Topics: Animals; Atazanavir Sulfate; Bilirubin; Cells, Cultured; Female; Glucuronosyltransferase; Glutathione Transferase; Hepatocytes; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Rats, Wistar; Ritonavir; Substance-Related Disorders | 2017 |
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Bilirubin; Drug Interactions; Female; Glucuronosyltransferase; Hepacivirus; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Ribavirin | 2008 |
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.
Topics: Adult; Alanine Transaminase; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Hyperbilirubinemia; Liver; Male; Multivariate Analysis; Oligopeptides; Prevalence; Proportional Hazards Models; Pyridines; Risk Factors; Ritonavir; Severity of Illness Index | 2009 |
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2010 |
Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bilirubin; Female; Gene Frequency; Genes, MDR; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Korea; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk Factors; Sequence Analysis, DNA; Severity of Illness Index | 2010 |
Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.
Topics: Adult; Alleles; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Female; Follow-Up Studies; Gene Frequency; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Incidence; Male; Middle Aged; Oligopeptides; Promoter Regions, Genetic; Pyridines; Republic of Korea | 2010 |
HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.
Topics: Adolescent; Adolescent Health Services; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Child; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Hyperbilirubinemia; Male; Oligopeptides; Pyridines; Spain | 2011 |
Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alleles; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Brazil; Cross-Sectional Studies; Female; Genotype; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Indinavir; Male; Oligopeptides; Predictive Value of Tests; Pyridines; Risk Factors; Severity of Illness Index | 2012 |
Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia, Hemolytic; Anti-HIV Agents; Anti-Infective Agents; Atazanavir Sulfate; Dapsone; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyridines | 2012 |
Severe atazanavir-associated hyperbilirubinemia revealing Canton G6PD deficiency in an Asian HIV-infected patient.
Topics: Adult; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Gilbert Disease; Glucosephosphate Dehydrogenase Deficiency; HIV Seropositivity; Humans; Hyperbilirubinemia; Male; Oligopeptides; Pyridines | 2012 |
Atazanavir-related hyperbilirubinaemia is not highlighted in the British National Formulary.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Delivery of Health Care; Female; Germany; HIV Infections; Humans; Hyperbilirubinemia; Jaundice; Oligopeptides; Pharmacopoeias as Topic; Practice Guidelines as Topic; Pyridines; Referral and Consultation; United Kingdom | 2012 |
Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Hispanic or Latino; HIV Infections; Humans; Hyperbilirubinemia; Incidence; Jaundice; Male; Middle Aged; Oligopeptides; Pyridines | 2013 |
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chemical and Drug Induced Liver Injury; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Indinavir; Oligopeptides; Pyridines | 2004 |
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; Genes, MDR; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Odds Ratio; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk Factors; RNA, Viral; Viral Load | 2006 |
Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.
Topics: Adult; Aged; Atazanavir Sulfate; Female; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; Haplotypes; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Pyridines | 2006 |
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Genes, MDR; Genotype; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Logistic Models; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk; Ritonavir | 2007 |
Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Middle Aged; Oligopeptides; Pyridines | 2007 |